Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

by Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, Hiu-Fung Yuen, Declan O'Rourke, Muhammad Babur, Brian A Telfer, Huw D Thomas, Patrick Keane, Thiagarajan Nambirajan, Chris Hagan, Joe M O'Sullivan, Chris Shaw, Kaye J Williams, Nicola J Curtin, David G Hirst, Tracy Robson
Published 2015-01-01